ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 44 citations in OpenAlex.
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Review
- Structural studies of the IFNλ4 receptor complex using cryoEM enabled by protein engineering.Nature communications · 2025Article
- Interferon lambda 4 is a gut antimicrobial protein.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T.Cancer research communications · 2024Article
- Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.Nature reviews. Urology · 2024Review
- Review
- The adverse characteristics of hepatocellular carcinoma in the non-cirrhotic liver disproportionately disadvantage Black patients.Cancer medicine · 2024Article
- Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort.Cancers · 2023Article
- The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer.Clinical and translational medicine · 2022Article
- Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race.European urology open science · 2022Article
- Distinct molecular phenotypes involving several human diseases are induced by IFN-λ3 and IFN-λ4 in monocyte-derived macrophages.Genes and immunity · 2022Article
- Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer.Nature communications · 2022Article
- Immune response and inflammation in cancer health disparities.Trends in cancer · 2022Review
- Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.Journal of the National Cancer Institute · 2022Article
- The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study.PLoS medicine · 2022Article
- Discordance in STING-Induced Activation and Cell Death Between Mouse and Human Dendritic Cell Populations.Frontiers in immunology · 2022Article
- Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.American journal of clinical and experimental urology · 2022Review
- JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.Carcinogenesis · 2021Article
- A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Wei TangLaboratory of Human Carcinogenesis, Center for Cancer Research (CCR), NCI, NIH, Bethesda, Maryland.
Tiffany A WallaceLaboratory of Human Carcinogenesis, Center for Cancer Research (CCR), NCI, NIH, Bethesda, Maryland.
Ming YiCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Cristina Magi-GalluzziDepartment of Pathology, Cleveland Clinic, Cleveland, Ohio.
Tiffany H DorseyLaboratory of Human Carcinogenesis, Center for Cancer Research (CCR), NCI, NIH, Bethesda, Maryland.
Olusegun O OnabajoLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Adeola ObajemuLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Symone V JordanLaboratory of Human Carcinogenesis, Center for Cancer Research (CCR), NCI, NIH, Bethesda, Maryland.
Christopher A LoffredoCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
Robert M StephensCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Robert H SilvermanDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
George R StarkDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Ludmila Prokunina-OlssonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-9622-2091
Stefan AmbsLaboratory of Human Carcinogenesis, Center for Cancer Research (CCR), NCI, NIH, Bethesda, Maryland. ambss@mail.nih.gov.
Center for Cancer Research · USNational Cancer Institute · USCleveland Clinic · USCleveland Clinic Lerner College of Medicine · USLeidos (United States) · USGeorgetown University · US
Funding
Laboratory of Translational GenomicsZIACP010201 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI PROKUNINA-OLSSON, LIUDMILA · 2010 to 2025
$91.2MMaryland Prostate Cancer Case-Control StudyZIABC010499 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2009 to 2025
$11.4MThe Molecular Profile of Prostate Tumors in African-American MenZIABC010624 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2009 to 2025
$8.0MANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE LR01AI135922 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI SILVERMAN, ROBERT H. · 2017 to 2021
$2.0MMaryland Prostate Cancer Case-Control StudyZ01BC010499 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2003 to 2008
$1.2MThe Molecular Profile of Prostate Tumors in African-American MenZ01BC010624 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2005 to 2008
$1.1MIntramural NIH HHS Z01 BC010499Intramural NIH HHS Z01 BC010624Intramural NIH HHS ZIA CP010201NIAID NIH HHS R01 AI135922
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllelesSequence DeletionBiomarkersGene Expression ProfilingGenotypeGerm-Line MutationHumansInterferon LambdaInterferonsInterleukinsMalePrognosisProstatic NeoplasmsRecurrenceTranscriptomeTryptophanBiomarkersIFNL4 protein, humanInterferon LambdaInterferonsInterleukinsTryptophan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.